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Commentary
DR. KRAMER COMMENTS ON PSY CHOACTIVITY OF CA LC IU M C HANN EL
BLOCKERS, CASE R EPORTS, AND RESEARCH
Sir:
Price and H eil are riding the wave of curiosit y about th e ro le o f ca lcium cha nnel
block ers in th e treatment of psychiatric di sorders. These authors, a sen ior reside nt and a
medical student, hav e taken time to r e view literatur e a nd to organize the ir o bservations
for publication. Dr. Pri ce has previousl y reported, in late 1985, on a fa irl y ca reful, bu t
nonparallel group design study on th e antipsychotic effec ts o f verapamil in eigh t
schizophrenics. These efforts are to be commended. It is th e appropriat e begin nin g fo r
more detailed and scholarly research. It would be e nc o urag ing to see more o f th is act ivit y
here and elsewhere.
Th e authors are aw are of some o f th e limitations of th eir specific co ncl usions and
those that , in general, ac company case reporting. While th e fo llow ing co mm ents are
somewhat specifically app licab le to Pri ce a nd H eil's present pap e r, th e y also serve to
di scuss the sho rtc o m ings of man y of th e case reports th at are publ ish ed th ese days.
Time alone, repeated " therape utic" contacts, and fluctuations in th e na tural course
of psychotic disorders are all factors which ma y influence o utco me m easu res. Fo r
instance, we have re cently co m p le ted a pla cebo-controlled double-blind st ud y o n the use
of two different adjuncti ve antidepressants in 90 schizoaffective, mainl y sch izo p hrenic,
patients. One minor and e xpected result was that th e patients, irrespective of th ei r
experimental treatment group assignment, were rated as significantly impro ved afte r
nine weeks of evaluation and treatment. This type of outcome sho u ld di ssuad e case
reporters from drawing an y but the most tentative co nclus io ns fr om a sa mp le of o ne. It is
also risk y to be decisive about the me aning of data co llec ted from a large sa mp le wit ho ut
parallel pla cebo or other parallel co ntrol groups.
Pri ce and Heil co uld have instituted a few simple d esign and wr ite -up techn iq ues tha t
ma y hav e allowed th em and us to make so me very tentative co nclus io ns:
I. Diagnosis. It is assumed that their patient was sch izop h re n ic. Th is should be
specifically stated, and, if possible, th e criteria m ethod o f di agnosis reported (DSM-Ill,
Feighner, Research Diagnostic Criteria, etc.),
2. Quantification of Outcome. A simple rating instrument , like th e Brief Psych ia t r ic
Rating Scale, could give us a better idea ofthe magnitude of th e beh avioral di stu rba nces
and improvement in the patient. In addition , an in strument like th e Scale for t he
Asse ssm ent of Negative Symptoms (SANS , Dr. Nan cy Andreason) co uld be e m p loyed in
an y future trials of verapamil in schizophrenia .
3. Repeated Crossovers. How would outcome m easures be influenced if t he a ut hors
swit ched th e patient ba ck to placebo, a nd th en to verapamil o r haloperidol again? A
positive relationship between improved outcome ratings o n ly during verapam il treat -
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ment periods would lend credence to the possible e fficacy o f ve rapamil in t his "schizophrenic" patient.
4. Unbias the Rater, Unbias the Patient. Patient and Rater e xpecta tions of trea tment outcome may significantly influence results. I am impressed with th e number of
patients who " im p ro ve dramatically" simply because of their transfer to a friendly
research unit, or upon receiving the new " m agic medicin e. " While I ma y bel ie ve t ha t thi s
placebo effect represents a "real" biological change in the patient , I mu st not allow
myself to conclude that the specific treatment, unless contrasted with placebo o r o t he r
control, is the important factor. I remember that during one of my double-bl ind
placebo-controlled studies, I tried to guess the identity of the encoded m edi cati on s. My
guesses were incorrect. Nevertheless, had I been an "unbl ind " rat e r, I wo u ld ha ve
unconsciously augm ented the outcome m easures of many of th e placebo-treat ed pati ents,
who I thought were being treated with active medications. If possible , it is worth wh ile to
co nsid e r en capsulating all medications within opaque capsules, a nd to util ize a b lind
rat er.
5 . Consider Alternative Reasons for an Apparent Treatment Effec t. Wh y do t he
negative (and positive) symptoms of schizophrenia seem to improve in thi s verapa mil treated patient? Perhaps the improvement was due to the patient's pre vio us respo nse
(improvement in positive symptoms) to haloperidol , time off neu rol eptics, subseque nt
diminution of neuroleptic-induced akinesia and sedation (improve me nt in nega tive
symptoms), and a further relapsing/remitting course, followed by relative remission.
This is not an unusual direction for schizophrenia, and could be independent of
verapamil treatment. We ne ed to be free of the m yth that sch izo p h re nics need co nsta nt
inpatient doses of neuroleptics. The emerging trend today is to treat th ese pati e nts wit h
very small doses of neuroleptics, until th eir target symptoms reemerge. This st rategy
seems to d imin ish the "negative" symptoms of schizophrenia. I think our " no ncompliant" patients have practiced this all along.
Eight months ago Drs. P. DeMaria, A. Mirow (b o t h J efferson resid ents) a nd m ysel f
co m p le ted a study and later submitted a paper for publication (u nde r revi e w), to t he
Journal of Clinical Psychopharmacology, on a double-blind , placebo-controll ed double
crossover study on the use of 60 mg (daily) of nifedipine (a calcium cha n ne l block e r) in
five DSM-lII diagnosed schizophrenics. In consideration of our sm all sample a nd lack of
parallel group design , we cautiously concluded that nifedipine lack ed a n a nt ipsyc hotic
e ffect. The patients appeared to be clinically less arnotivated, an ergic, and/or asocia l.
Yet, this finding was not corroborated by specific BPRS item scores, nor co n fined to th e
nifedipine period. One patient did " im p rove dramatically" (clinically and wit h BPRS
decreases of about 35 percent), but this also was not co n fine d to th e ac tive treatme nt
period. One patient had about a 25 percent in crease in BPRS scores after neu rol eptic
withdrawal and placebo or nifedipine treatments. While it can be argued that ni fedipine
was effective in one patient, it is more likely that neuroleptic withdrawal was respon sibl e
for the apparent activation and other alterations in clinical sta te of mo st of th e pati e nt s.
There is the remote possibility that nifedipine ma y have potential e fficacy for t he
negative symptoms of schizophrenia. However, we've decided to fir st in vest igate wheth e r
nifedipine is an antidepressant. Drs. K. Caputo, L. Maldonado , A. Mirow , and F.
Sholevar, all Jefferson residents, have joined me in this investigation of nifedipine in ten
e ndoge no usly depressed patients. We are more than half-w a y through thi s double-bl ind
sym m e tr ica l placebo-controlled crossover trial.
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I hope t ha t t hese co m ments will not discourage case repor ting, but ra t he r will serve
as so me g u idelines for e n hanced cli nical case reporti ng, a nd as an indi ca tion for th e
necessit y of su bse quent ca refu lly d esign ed , large r studies .
Mark Kra mer, M.D ., Ph. D.
H ead of Division of Biol ogica l Psychiatry
J effe r so n Med ica l College
C h ief of Sc h izophrenia Resea rch
Coatesville Ve terans Administration Medi cal Ce nter
[Our wo r k mention ed here
Program .]

IS

supported as part of the VA Merit Re vie w Grant

DR . SH O RE CO MMENTS O N "T REATMENT OF THE NEGATIVE
SY M PTO MS OF SC H IZO PH REN IA WI TH VE RAPAMIL"
Sir:
It is e ncouraging to see pape rs on ne w trea t me nt app roaches to sch izo p hrenia,
especially those ta rge te d o n nega tive sym ptoms. W hi le case reports ma y have limited
scientific va lue, th e y are an excellen t mea ns by whic h o ne can progress from clini cal
observation to a resea rch o r ienta tio n. Re vie wing t he litera tu re on a topic, synthes izin g a
variety of views and h yp otheses, evaluating a t herapeutic trial, and writ ing up th e res u lts
in a resea rch pape r ca n all serve as im portant lea r n in g e xpe r ie nces. Man y research
scientists ha ve begun wit h case reports and t hen gone on to learn bl ind assessm e nt
tec h niques, dat a ana lysis, an d a host of methodologica l refinements. I beli eve t ha t th e
a u t hors of th is a rt icle ha ve go tten a pro mi sin g start a nd I en courage th em to co nsider
fur t her researc h on sch izo p hre nia .
I was going to p repa re a cri tiq ue of t he pape r t ha t wou ld illustrate th e utility and th e
po tentia l pitfa lls of case re po rt studies, b ut after reading Dr. Kramer's e xce llent
co m men tary, writing one m yself see ms un necessar y. His review of factors such as pl acebo
effects in non-b lind studies, r elat ed p robl ems wit h subjective vs. more objective assessments , a nd variations in th e na tural co urse of psyc h iatric disorders such as schizophren ia ,
is very va luable. I, too , ha ve gotten excited over treatment responses in patients who
turned o u t to be o n p lacebo. Since t he pa tie nt, wa rd staff, and ph ysician all wan t (and
per haps ex pect) t he pati e nt to get bette r , it is no surprise when that seems to occ ur.
Crossover st ud ies (suc h as th e A/ B/ A design: p lacebo/active drug/placebo period s) can
be very useful , bu t even with this design patients ma y seem to respond well to the ac tive
dru g, b ut when lat e r p laced back on the d ru g (A/B/ A/B design), blind assessm en t ma y
fa il to show the sa me positive response .
Anot her area t hat can be pro ble ma tic for developing research ers is th e lite rature
re vie w. It is a na t ural tenden cy to search for pape rs or other indications that a particul a r
h ypo th esis, approach o r d ru g is pro m ising . Nevertheless , one must search at lea st as hard
for evidence co ntra ry to o ne's idea- some tim es we can avoid reinventing wheels,
so metimes we can de vise new specu lat ions to explain contradictory results. Of course,
u nl ess one has firsthand ex perience wit h a given technique, assessment, or assa y, it is hard
to evaluate conflicting litera ture . Reside nts are at anot her disadvantage in th at th ey may
not kn o w of recently complet ed or ongoing studies. T hose who are ab le to read a large
numbe r of scienti fic journals, t hose who may lea rn of new studies from rev iewin g art icles
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for various journals or from reviewing grant applications, and those who personally know
other scientists working in a given field obviously ha ve an advantage. But none of these
are in surmountable, and just as clinicians graduall y grow in skills a nd kno wled ge , so
researchers develop and learn with wh om th e y shou ld co llaborate or consult , what
meetings they sh o u ld attend, and what journals they sh ould read.
Because of the programs and priorities of the National Institute of Mental Heal th
(N I MH) , I am convinced that this is a particularly ex citing tim e for psychi a t ry res iden ts
interested in schi zophrenia research. There are a number of research , ca ree r development, and research training mechanism s a vailable through N IM H gra nts a nd intramural
programs, a nd I would encourage all those interested in sch izo ph re nia research to learn
about th ese opportunities. A summary of NIMH schi zophrenia resea rch p rograms of
particular relevance for psychiatry residents follows .
David Shore , M.D .
Chie f, Biol ogi cal a nd Clinical Factors Resea rch Program
Schizoph renia Research Bran ch
Division o f Clinical Res earch
National Institute of Mental H ealth

SCHIZOPHRENIA RESEARCH CAREER OPPORT U NI TI ES

Schizophrenia affects at least 1 percent of the population and has been
est imate d to cost the U.S. over 20 billion dollars per yea r in treatm e n t costs and
lost income . Psychiatric residents are wel l a ware of th e se ve re di sability caused
by sch izop h re n ia and th e limits of cu r re ntly available treatm ents. Nevertheless,
with the many career options open to th em , sch izo p h re n ia research is too often
overlooked.
Th e climate for schizophrenia research ha s be en changing recentl y, so that
an academic career in this field could be particularly exc it ing. T he co nvergence
o f sev e ra l facto rs, especiall y the man y recent advan ces in th e ne u roscie nces,
makes those of us on th e staff of th e Nation al Institute o f Mental H ealth (NIMH)
very e nth usiastic about new opportunities . With th e introducti on o f noninvasive scanners such as the CT, MRl , CBF, and PET, research ers have bee n
able to examine the structure and function of th e brains o f schi zo p h re nic
patients. These st ud ies ha ve d emonstrated subtle atrophy in schizophrenic
patients' brains and sh o wn differences in metabolism and receptor density
co m pared to co n tro ls. Along with the e me r ge nce of these sop h isticate d scanning
methods, the biological theories of schizophrenia have al so gain ed mome ntu m.
Examples of this trend include the increase in studies o f neurotran smitte rs and
th eir metabolites, pharmacological trials with " stat e of th e scienc e " a ntipsych otic m edications, measurement of peptides that fun cti on as neuromodulato rs,
physiological measures such as eye tracking, and molecular gen eti cs.
These advances in clinical applications of ba sic scie nce adva nces are ,
however, onl y part of th e reason th ere is increased e n t h us iasm in schizop hrenia
research . In th e late 1970s, famil y groups began to o rga n ize to d ecrease thei r
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isol ation a nd advocat e for bette r mental health ca re. T hese fami ly groups have
become a political fo rce, pressin g legi slators to d o more in t he areas of treatment
a nd r esearch on maj or mental illn esses, a nd th e y ha ve lobb ied successfull y in
Congress for in crea sed fu nd ing o f sch izo p h ren ia research a nd research trainin g.
Resid ents sho u ld be informed th at resea rc h o n maj o r me nt a l illnesses such
as sc h izo p h ren ia has become a leadin g priority o f N IM H . T he Institute is
es pecia lly co ncerned a bou t sch izo p hre n ia research manpo we r needs, and has
been exp lo r ing in centives to de vel op a new genera tion of research scientists.
Giv en th e sh ift toward a more bi ol ogi cal approach to sc h izo p hrenia, psychiatry
r esid ents and others with biom edical train ing h a ve specia l p ote n ti al for making
co nt r ib ut io ns to sch izo p h re n ia research progress in t he co mi ng years. Rapidly
d e veloping areas su ch as mol ecular genet ics, neurovirol ogy, neu r och e m istr y,
st ru ctu ra l and fun ctional imagin g, and psychopharmacol ogy a ll h ol d the potential for breakthroughs in schizophreni a rese a rc h.
Of co u rse , r esearch is not for e ve r yo ne, a nd th ere ha ve bee n n u merous
di sin centives to schi zophrenia r es earch careers as noted in th e Spring 19 86 issue
o f Schizophrenia Bulletin (1). One of th e problems is that , unless a person has been
inv olv ed in resea r ch , the re is no su re wa y to d etermine whether he or she would
be happy in suc h a r ol e. Medical stu den ts a nd r esid ents in te r ested in research
shou ld see k o u t o p portu n ities fo r suc h e xper ie nce with successfu l investigators.
Man y psychiatry d epartments ha ve o ngoing r esearch p rojects, a nd N IMH can
provid e lists of sch izo p h ren ia research gran ts fu nded in r ecen t yea rs at institutio ns a ll arou nd th e co u ntry . T hese a re summa r ized in t he upcom ing issues of
th e Schizophrenia Bulletin, Volume 13 , umbe rs 1 an d 2. If a give n institution
does no t ha ve a r esearch er or p r ogram in o ne's area of interest, a fe llowship to
stu dy wit h a mentor elsew here ma y b e worth co ns ider ing. In addi t ion to he lping
a potential research tra in ee d ecide a bou t th e d esir abil it y of this career option,
e xper ie nce in r esearch (a nd publicati on ) is im porta nt in th e r e vie w of research
trainin g ap p lica t io ns.
N IM H now offers th ree research su pport mech an ism s, two research scientist d e velopment mech ani sm s, an d two research tra in ing mech a n ism s for support o f d e veloping inv estigators. As a result o f thi s wid e va r iety of opportunities,
it is o ft en uncl ear to the poten tial ap p lica nt wh ich o p por tu n ity is best suited to
his or her needs. As a first ste p , a potential applicant needs to be kn owledgea ble
a bo u t what these different mechanisms were d ev el oped to accom p lish, as well as
th e deta ils of their administrative req u iremen ts.
1. Research Support Me chanism s: All three of th ese mecha nisms mainly

provide sup por t for research cos ts, but th e applicant ca n ass ign a part of
the budget for his or h er ow n sa lary or for th e sa lary of research
personnel.
A. Small Grant: T he small gran ts mech anism was d e vel oped to provide
funds fo r pil o t wo r k o r sta r t up fu nds fo r ne w in vest iga to rs. Funds
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are available to a maximum of $ 25, 00 0 for a period limi ted to one
yea r (extensions without additional funds are routinel y avai lable).
This mechanism is best su ite d for di scretel y d efined studies that can
be completed in about a yea r within this fu nd ing limi tatio n . It has
been used successfully in th e past b y beginning in vest igato rs.
B. RO I: The inv estigator-initiated researc h gra n t is the bread and
butter research funding mechanism o f IMH. It p rovid es research
funds for qualified applicants at qualified insti tutio ns; up to five
years of funding can be requested with a fu nd ing lim it dete rmined
by th e fiscal needs of th e supported research. T h is mech an ism is
best suited for support of relatively complex stu dies th at req u ire
multiple years of suppo r t and ma y be part of a long-r ange program
of research . It has often been used in th e past by beginn ing
investigators whose work does not fit within th e co nfi nes of the
small grant.
C. FIRST: A new res earch funding mechanism at NIMH designed to
provide salary and research support to th e in vesti gator who has
never before been the princip al investigator on a Public Heal t h
service funded grant. This mechanism provides up to $ 100, 000 per
yea r fo r up to five yea rs of su ppo rt, with a total fu ndi ng lim it of
$350,000 ; the funds can be used for both salary a nd th e support of
research expenses. Because of its five yea r durati on an d relatively
large funding limit, th e applicants must ha ve a we ll th o ugh t out
program of research to su ppo rt these limits. T h is is a ne w program
and there is no track rec ord regarding th e re vie w groups' reaction
to th ese ap p lica t io ns. The Institute hopes tha t th e rev iewers will
look upon th ese as opportunities to a llow bright, ca pa ble young
in vestigators to begin a research career.
II. Research Scientist Development Award (RSDA) Mech ani sm s: These

are designed primarily to provide salary su pport a nd researc h training
opportunities for d eveloping scientists. Limited fu nds can be requested
for research sup po r t.
A. Physician Scientist Award (PSA): This a ward is d esign ed to e nhance
the development of ph ysicians in research ca reers . Five years of
support for salary, as well as up to $10,000 per year for research and
training costs for the first three yea rs and up to $ 20, 000 per year
for the final two years of support ca n be requested. Ph ysicia ns with
little res earch expe r ience have found thi s mechanism to be quite
helpful as th e y develop into research scie n tists. A m inimu m of two
years of post-doctoral ex per ie nc e is required before sup port can be
granted .
.
B. Research Scientist De velopment Award (RSDA) Le vel I: This
award is d esign ed to sup por t indi vidual s with outstandin g research
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potential who need further super vised research ex perience. App licants are usually scientists or clinicians with so me research experience or scientists prepared in one di scipline wh o need su pervised
experience in another. Five yea rs of salary, research , and research
training costs ca n be requested. This me chanism has bee n remarkably successful in helping yo u n g investigators d e vel op into independ ent scientists. A minimum of three yea rs of post-doctoral experience is required before support ca n be granted.
III. Research Training Mechanisms: In th ese programs, th e p rim a r y goa l is
to provide support during a research training interval. Both a re fo r a
maximum of three years of post-doctoral training.

A. National Research Scientist Award (N RSA) Indi vidual Fe llo wsh ip :
This award is designed to provide stipend sup port during resea rch
training. Prior to formal submission , th e ap plica n t must arrange
acceptance by a sponsor who will supervise th e research train ing
expe r ie nc e in a facility that has an appropriate e nv iron ment to
provide the proposed research training . Po st-docto ral stipends
range from $ 16 ,000 to $ 30 ,00 0 per yea r depending on yea rs of
experience. In addition , $3,000 ma y be requested fo r institution al
allowances .
B. Public Health Service (P HS) Epidemiology Fell o wsh ip : T his award
is somewhat different from th e other awards d escribed a bove in
that the first year of suppo r t is for training leading to an MPH a nd
the second a nd third yea rs of sup po rt a re for research experience in
epidemiology at th e NIMH. Recipi ents o f th ese awards receive
NIMH appointments equivalent to the intramu ral Clin ica l Associates. Salary support begins at $30,000 for th e first year wit h
$2,000 increments for each yea r of su p por t. T he pu rpose of th is
program is to increase th e number of medical p ro fessionals in
mental health epidemiology.
IV . NIMH Intramural Research Programs (I R P): Medical Staff (Clin ical
Associate) Fellowships at
IMH in Bethesda o r at St. Elizabeth's
Hospital in Washington, DC, a r e a vailable for th o se wh o a re co mpleting or have completed residency training. Unlike th e ex t ra mural gra n t
programs described in I-III above , th e IRP co nd uc ts research o n its
own cam p uses, rather than providing g ra n ts to o ther institu tio ns.
There are active research p rograms in sch izo p h ren ia, affec tive and
anxiety disorders, basic neuroscience , imaging, e tc. Medical staff fe llowships are for two yea rs, with a sta r t in g annual sala r y o f $32,00 0.
Th e events described ea rl ie r ha ve pro vid ed th e impetus fo r increased
sup po r t for caree rs in schizophrenia research, but mone y and research tools are
not in themselves a reason to make a career decision. Th e most co m pelling
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reason for more residents and medical students to lo ok at a career in schi zophrenia research is that these seriousl y ill patients need th e help of d ed icated and
e nerge t ic ph ysicians. De veloping research psychiatri sts no w have increased
opportunities to contribute to adva nce s in findin g th e e t iology o r bette r
treatm ents for this se ve re and chronic mental di sorder.
David Shore , M.D.
Chie f, Biological and Clin ica l
Factors Research Program
Schizophrenia Research Br an ch
Division o f Clin ica l Resea rch
Na tio na l In stitute o f Mental Health
Leonard Lash , Ph.D.
Associate Director for Research Training a nd
Research Resources
Division of Clinical Research
Na tio na l In stitute of Me ntal Heal t h
S. Charles Schulz, M.D.
Chief, Pharmacologic and So matic
Treatments Resea rch Progra m
Schizophrenia Resea rch Br an ch
Division o f C lin ica l Research
a tio na l In stitute o f Mental H eal t h
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